Liverpool HIV Interactions

Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

No Interaction Expected

Doravirine (DOR)

Ethinylestradiol

Quality of Evidence: Low

Summary:

Coadministration of doravirine (100 mg once daily) and ethinylestradiol/levonorgestrel (0.03/0.15 mg once daily) did not significantly impair ethinylestradiol, levonorgrestrel and doravirine exposures. Ethinylestradiol AUC and Cmax decreased by 2% and 17%; levonorgestrel AUC increased by 21% and Cmax decreased 4% (n=20). Note, use of ethinylestradiol as part of gender affirming treatment is not recommended due to thrombotic risks.

Description:

Co-administration of ethinyl estradiol/levonorgestrel (0.03/0.15 mg single dose) and doravirine (100 mg once daily) decreased ethinyl estradiol AUC and Cmax by 2% and 17%; levonorgestrel AUC increased 21% and Cmax decreased by 4%. No dose adjustment is necessary.

Pifeltro Summary of Product Characteristics, Merck Sharp & Dohme Ltd, November 2018.

No clinically significant changes in ethinyl estradiol and levonorgestrel concentrations was observed when an oral contraceptive was coadministered with doravirine.

Pifeltro US Prescribing Information, Merck & Co Inc, August 2018.

Co-administration of doravirine (100 mg, once daily, for 17 days) with ethinylestradiol/levonorgestrel (0.03/0.15 mg, single dose) was studied in 20 healthy female subjects. Ethinylestradiol AUC and Cmax were reduced by 2% and 17%, respectively, while levonorgestrel AUC was increased by 21% and Cmax decreased 4%. Changes to contraceptive pharmacokinetic parameters were not considered clinically relevant.

Effect of doravirine (MK-1439) on the pharmacokinetics of an oral contraceptive (ethinyl estradiol [EE] and levonorgestrel [LNG]. Anderson MS, Kaufman P, Castronuovo P, et al., 16th International Workshop on Clinical Pharmacology of Antiviral Therapy, Washington, May 2015, abstract: 60.

View all available interactions with Doravirine (DOR) by clicking here.